325 Participants Needed

RF Ablation for Atrial Fibrillation

Recruiting at 11 trial locations
DB
WB
CM
Overseen ByCaroline Mazzola
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: AtriCure, Inc.
Must be taking: Class I/III AAD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it mentions that participants should be refractory or intolerant to at least one antiarrhythmic drug (AAD), which might imply changes to your current medication regimen.

What data supports the effectiveness of the treatment EPi-Sense Guided Coagulation System for atrial fibrillation?

The Convergent Procedure, which involves epicardial and endocardial ablation, has shown a success rate of 80% in treating persistent atrial fibrillation, suggesting that similar epicardial ablation techniques like the EPi-Sense Guided Coagulation System may also be effective.12345

Is RF Ablation for Atrial Fibrillation generally safe for humans?

The research articles provided do not contain specific safety data for RF Ablation for Atrial Fibrillation or the related devices mentioned.13467

How is the EPi-Sense Guided Coagulation System treatment for atrial fibrillation different from other treatments?

The EPi-Sense Guided Coagulation System is unique because it involves a minimally invasive surgical procedure that uses a suction support adapter to ensure effective contact between the ablation probe and the heart tissue, aiming for thorough coagulation. This approach is different from standard catheter-based ablation techniques and can be used as a stand-alone procedure or in combination with other cardiac surgeries.348910

Eligibility Criteria

This trial is for adults aged 18-79 with symptomatic long-standing persistent atrial fibrillation, who haven't responded to certain antiarrhythmic drugs. Participants must have a life expectancy over a year and a left atrium size ≤ 6.0 cm. Exclusions include pregnancy, severe heart failure, treatment for ventricular arrhythmias, recent participation in other trials, cognitive impairment affecting consent ability, and various medical conditions that could interfere with the study or are risks due to the procedure.

Inclusion Criteria

Life expectancy > 12 months
Provides written informed consent
Left atrium ≤ 6.0 cm assessed with Transthoracic Echocardiography [TTE] with parasternal 4 chamber view or equivalent imaging modality
See 3 more

Exclusion Criteria

I have Barrett's esophagus.
Pregnant or planning to become pregnant during study
Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo the Hybrid Convergent procedure using the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation.

1 day (procedure)
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the procedure, including evaluation of freedom from AF/AT/AFL and incidence of adverse events.

12 months
Multiple visits (in-person and virtual) over 12 months

Long-term Follow-up

Participants' long-term outcomes are assessed, including quality of life and freedom from AF/AT/AFL over 3 years.

3 years

Treatment Details

Interventions

  • EPi-Sense Guided Coagulation System
Trial OverviewThe CONVERGE PAS study tests the EPi-Sense® Guided Coagulation System's effectiveness and safety when used commercially on patients with long-standing persistent AF who don't respond well to standard treatments. It involves epicardial and endocardial radiofrequency ablation—a technique using heat energy to destroy problematic heart tissue causing irregular rhythms.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Hybrid ConvergentExperimental Treatment1 Intervention
Once the procedure intra-op exclusion conditions have been evaluated, the Epicardial linear lesions will be created endoscopically using the EPi-Sense®-Guided Coagulation System or EPi-Sense ST™ Coagulation System throughout the posterior left atrium and along the pericardial reflections from a trans-diaphragmatic or sub-xyphoid access without any chest incisions. An endocardial ablation catheter will be used to complete the isolation of the pulmonary veins and create a cavotricuspid lesion to prevent typical atrial flutter. Posterior and other linear lesions such as a roof lesion and mitral valve isthmus lesion will not be created during the endocardial component of the convergent procedure. Once the study lesion pattern has been created by coagulating cardiac tissue using the EPi-Sense®- Guided Coagulation System or EPi-Sense ST™ Coagulation System and the endocardial ablation catheter, the pulmonary veins must be evaluated for entrance and/or exit block to confirm isolation.

EPi-Sense Guided Coagulation System is already approved in United States for the following indications:

🇺🇸
Approved in United States as EPi-Sense Guided Coagulation System for:
  • Symptomatic long-standing persistent atrial fibrillation in patients who are refractory or intolerant to at least one Class I and/or III antiarrhythmic drug (AAD)

Find a Clinic Near You

Who Is Running the Clinical Trial?

AtriCure, Inc.

Lead Sponsor

Trials
43
Recruited
22,800+

Findings from Research

The use of an infrared coagulator on the beating heart during a coronary artery bypass graft procedure successfully restored sinus rhythm in a patient with atrial fibrillation.
Postoperative electrophysiologic studies confirmed that the infrared coagulator created a bidirectional block in the right atrial appendage, suggesting its potential to enhance the epicardial Maze procedure for treating atrial fibrillation.
Epicardial electrical isolation of the right atrial appendage on the beating heart with an infrared coagulator.Kubota, H., Sudo, K., Takamoto, S., et al.[2016]
A systematic study using a biophysical model of human atria found that certain ablation line patterns for treating atrial fibrillation can achieve high success rates, with up to 90-100% conversion rates when combining lines from both the right and left atria.
The study identified that a single closed line for pulmonary vein isolation yielded a 55% success rate, while the inclusion of a left isthmus line was crucial in preventing uncommon left atrial flutter, suggesting that fewer lines can still be effective compared to traditional methods.
A biophysical model of atrial fibrillation ablation: what can a surgeon learn from a computer model?Ruchat, P., Virag, N., Dang, L., et al.[2008]
The suction support adapter significantly improved the effectiveness of epicardial ablation on a beating heart, achieving deeper and narrower coagulation compared to using the ablation probe alone, as demonstrated in a study with 12 pigs.
All cases using the adapter resulted in successful electrical isolation of the atrial wall, while only one case without the adapter achieved this, indicating that the device enhances the safety and reliability of the procedure.
A new instrument of suction support adapter system for epicardial radiofrequency ablation.Kadoya, S., Watanabe, G., Koshida, Y., et al.[2010]

References

Epicardial electrical isolation of the right atrial appendage on the beating heart with an infrared coagulator. [2016]
A biophysical model of atrial fibrillation ablation: what can a surgeon learn from a computer model? [2008]
A new instrument of suction support adapter system for epicardial radiofrequency ablation. [2010]
Epicardial box lesion using bipolar biparietal radiofrequency and multimodality scar evaluation-a case series. [2022]
The Convergent Procedure - A Standardised and Anatomic Approach Addresses the Clinical and Economic Unmet Needs of the Persistent Atrial Fibrillation Population. [2020]
Analysis of catheter contact force during atrial fibrillation ablation using the robotic navigation system: results from a randomized study. [2018]
Simultaneous assessment of contact pressure and local electrical coupling index using robotic navigation. [2021]
[Surgical atrial fibrillation ablation therapy and postoperative monitoring]. [2021]
Atricure bipolar radiofrequency clamp for intraoperative ablation of atrial fibrillation. [2019]
Impact of respiration gating on image integration guided atrial fibrillation ablation. [2021]